MedTrace Logo

HAIC-TACE Plus Apatinib and Camrelizumab for Liver Cancer

NCT07587034 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 315

Last updated 2026-05-20

No results posted yet for this study

Summary

To provide evidence-based medical evidence for the optimized combination strategy of local and systemic therapies.

Conditions

Interventions

PROCEDURE

HTAC

Patients will first undergo hepatic arterial infusion chemotherapy (HAIC) treatment. Subsequently, transarterial chemoembolization (TACE) will be administered sequentially following the completion of HAIC. This regimen will be combined with apatinib (a vascular endothelial growth factor receptor 2 \[VEGFR-2\] inhibitor) and camrelizumab (a programmed cell death protein 1 \[PD-1\] inhibitor) therapy.

PROCEDURE

HAC

Patients will receive a combination therapy consisting of HAIC, apatinib, and camrelizumab.

PROCEDURE

TAC

Patients will be treated with a regimen combining TACE, apatinib, and camrelizumab.

Sponsors & Collaborators

  • Affiliated Hospital of Nantong University

    collaborator OTHER

  • Nantong First People's Hospital

    collaborator OTHER

  • The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China

    collaborator OTHER

  • Shandong Public Health Clinical Center

    collaborator OTHER_GOV

  • Shanghai Xuhui Hospital

    collaborator UNKNOWN

  • The fifth Hospital Affiliated To WZMU

    collaborator UNKNOWN

  • Shanghai Zhongshan Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2029-12-31
Completion
2029-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07587034 on ClinicalTrials.gov